Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EBIT (2016 - 2025)

Historic EBIT for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $197000.0.

  • Harvard Bioscience's EBIT rose 11051.23% to $197000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.3 million, marking a year-over-year decrease of 74644.78%. This contributed to the annual value of -$6.2 million for FY2024, which is 42793.03% down from last year.
  • Per Harvard Bioscience's latest filing, its EBIT stood at $197000.0 for Q3 2025, which was up 11051.23% from -$819000.0 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's EBIT peaked at $4.0 million during Q2 2022, and registered a low of -$49.7 million during Q1 2025.
  • Its 5-year average for EBIT is -$3.1 million, with a median of -$239000.0 in 2021.
  • Data for Harvard Bioscience's EBIT shows a peak YoY increase of 679310.34% (in 2022) and a maximum YoY decrease of 270836.82% (in 2022) over the last 5 years.
  • Harvard Bioscience's EBIT (Quarter) stood at $1.7 million in 2021, then crashed by 126.9% to -$457000.0 in 2022, then surged by 161.71% to $282000.0 in 2023, then crashed by 96.1% to $11000.0 in 2024, then soared by 1690.91% to $197000.0 in 2025.
  • Its last three reported values are $197000.0 in Q3 2025, -$819000.0 for Q2 2025, and -$49.7 million during Q1 2025.